Autologous tumor infiltrating lymphocytes (University Health Network, Toronto)

自体肿瘤浸润淋巴细胞（University Health Network）

Report date: 2026/04/17 10:36:13

Base Information

Drug NameAutologous tumor infiltrating lymphocytes (University Health Network, Toronto)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionLymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsMesothelioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Health Network (Uhn)

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Health Network (Uhn)

Active IndicationsN/A

Inactive IndicationsMesothelioma

Other Information

ATC CodeN/A